"Watch and wait” is typically used first for asymptomatic patients with myelofibrosis, according to a retrospective review of management strategies from the United Kingdom.
A retrospective review presented recently showed the diverse range of management strategies used for patients with myelofibrosis (MF), where “watch and wait” is typically used first for asymptomatic patients.
An interim analysis from a UK study was presented at the British Society for Haematology Annual Scientific Meeting. Real-world data on the management of patients with MF are limited, and the REALISM study aimed to document the early management pathways in routine clinical practice. The primary endpoint was the time from diagnosis to active treatment.
REALISM UK is a multi-center, non-interventional study ongoing in 15 UK secondary care centers. Eligible patients were older than 18 years at diagnosis, with diagnosis greater than 6 months and 5 or more years prior to data collection and with 1 or more follow-up visits. Data on patient demographics, clinical characteristics, MF management strategies and outcomes were collected from patients’ medical records; the observation period was from the date of MF diagnosis until data collection.
The study included 200 patients, with 64% having primary MF and 36% having secondary MF. The median age at MF diagnosis was 69.7 (interquartile range [IQR] 63.5—75.7) years; 63% (125/200) had a Janus kinase 2 (JAK2) gene mutation. The International Prognostic Scoring System category for 60% of the patients was an intermediate-2 or high at diagnosis.
Symptoms of disease at diagnosis included an enlarged spleen (47%), anemia (44%), and constitutional symptoms such as night sweats, unexplained fever or weight loss (30%).
The median time from diagnosis to active treatment was 0.0 (IQR 0.0—369.3) days (n = 200). During the study observation period “watch and wait” was the first management strategy for 47% (94/200) of patients (primary MF, 56% [71/127]; secondary MF, 32% [23/73]), with 69% (65/94) progressing to active treatment.
In the 94 patients who progressed to active treatment (including 29 with no active treatment at data collection), the median (IQR) time from diagnosis to active treatment (or data collection) was 409 days. Those scored low intermediate progressed at 280.5 days; those scored intermediate-1 were 284.5 days; those scored intermediate-2 were 461 days; and those scored high were 119 days.
Active treatment was started at diagnosis for 53% of patients. A total of 409 management strategies (defined as any clinical decision on patient management) were observed. Watch and wait was the most used strategy (26% [107/409]), followed by ruxolitinib (25% [102/409]), hydroxycarbamide (17% [68/409]) and allogenic stem cell transplantation (3% [11/409]).
The median treatment duration during the observation period was 398 (IQR 180.3—699.3) days for ruxolitinib and 336.5 (IQR 108.5–767.5) days for hydroxycarbamide.
Nearly one-fourth of patients died between diagnosis and data collection. The recorded causes of death were: MF-related (38%), other malignancies (9%), infection (9%), and heart failure (6%). The cause was unknown in 38% of cases.
Reference
Mead A, Butt N, Nagi W, et al. A retrospective real world evidence study to review the current treatment pathways for myelofibrosis from across the United Kingdom (The REALISM UK Study). Presented at the British Society for Haematology Annual Scientific Meeting; April 1-3, 2019; Glasgow, Scotland. Abstract BSH19-OR-008.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More